Atorvastatin

Generic Name: Atorvastatin

Brand Names: Atorvaliq, Caduet, Lipitor, Lypqozet

Drug Type: Small Molecule

Chemical Formula: C_₃₃H_₃₅FN_₂O_₅

CAS Number: 134523-00-5

Unique Ingredient Identifier: A0JWA85V8F

Background: Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylg...

Indication: Atorvastatin is indicated for the treatment of several types of dyslipidemias, including primary hyperlipidemia and mixed dyslipidemia in adults, hypertriglyceridemia, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia, and heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modifications.
...

Associated Conditions: Anginal Pain, Cardiovascular Complications, Cardiovascular Disease (CVD), Coronary Artery Disease (CAD), Coronary artery thrombosis, Dysbetalipoproteinemia, Fredrickson Type III lipidemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hospitalizations, Hypertension, Essential Hypertension, Hypertriglyceridemias, Mixed Dyslipidemias, Mixed Hyperlipidemia, Myocardial Infarction, Non-familial hypercholesterolemia, Nonfatal Myocardial Infarction, Postoperative Thromboembolism, Primary Hypercholesterolemia, Stroke, Thrombosis, Transient Ischemic Attack, Elevation of serum triglyceride levels, Heterozygous familial hyperlipidemia, Non-familial hyperlipidemia, Primary Hyperlipidemia, Revascularization procedures

Associated Therapies: -

Clinical Trials

Study of Atorvastatin Versus Placebo to Reduce Cardiopulmonary Complications After Thoracic Surgery

Not Applicable

Completed

Conditions: Thoracic Surgery

Interventions: Drug: Atorvastatin
Drug: Placebo

First Posted Date: 2006-09-13

Last Posted Date: 2021-01-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 162

Registration Number: NCT00375518

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, New York, United States

Effects Of Atorvastatin On Macrophage Activity And Plaque Inflammation Using Magnetic Resonance Imaging

Completed

Conditions: Atherosclerotic Carotid Disease
Atheroma
Atherosclerosis

First Posted Date: 2006-08-24

Last Posted Date: 2015-04-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 47

Registration Number: NCT00368589

Locations: 🇬🇧
GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom

Randomized Placebo-Controlled Trial of Atorvastatin in HIV-Positive Patients Not on Antiretroviral Therapy

Phase 2

Completed

Conditions: HIV

Interventions: Drug: Atorvastatin
Drug: Placebo

First Posted Date: 2006-08-23

Last Posted Date: 2020-02-26

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 24

Registration Number: NCT00367458

Locations: 🇺🇸
Naval Medical Center, San Diego, San Diego, California, United States
🇺🇸
National Naval Medical Center, Bethesda, Maryland, United States
🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Comparison of the Combination of Fenofibrate and Simvastatin Versus Atorvastatin

Phase 3

Completed

Conditions: Hyperlipidemia

Interventions: Drug: fenofibrate / simvastatin
Drug: Atorvastatin

First Posted Date: 2006-08-15

Last Posted Date: 2009-07-08

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 516

Registration Number: NCT00362934

Locations: 🇺🇦
Site 412, Kiev, Ukraine
🇺🇦
Site 415, Zaporozhye, Ukraine
🇧🇬
Site 500, Sofia, Bulgaria

and more 65 locations

Systemic Immunomodulatory Effects and Pharmacogenetics of Atorvastatin in Early Atherosclerosis

Phase 4

Completed

Conditions: Inflammation

Interventions: Drug: Atorvastatin

First Posted Date: 2006-08-08

Last Posted Date: 2012-05-15

Lead Sponsor: University of Florida

Target Recruit Count: 108

Registration Number: NCT00361283

Locations: 🇺🇸
University of Florida, Gainesville, Florida, United States

Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents

Phase 2

Completed

Conditions: Healthy

First Posted Date: 2006-08-02

Last Posted Date: 2018-02-23

Lead Sponsor: Aegerion Pharmaceuticals, Inc.

Target Recruit Count: 125

Registration Number: NCT00359281

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Effects of Atorvastatin on Disease Activity and HDL Cholesterol Function in Patients With Rheumatoid Arthritis

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Atorvastatin

First Posted Date: 2006-07-26

Last Posted Date: 2012-06-22

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 20

Registration Number: NCT00356473

Follow-On Study of Pitavastatin Versus Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia

Phase 3

Completed

Conditions: Type II Diabetes Mellitus
Dyslipidemia

Interventions: Drug: Pitavastatin
Drug: Atorvastatin

First Posted Date: 2006-06-26

Last Posted Date: 2010-02-02

Lead Sponsor: Kowa Research Europe

Target Recruit Count: 214

Registration Number: NCT00344370

Locations: 🇮🇳
Sri Ramachandra Medical College Hospital, Chennai, India
🇮🇳
Apollo Hospitals, Hyderabaad, India
🇵🇱
Szpital Wolski,im. Dr A. Gostynskiej, Warszawa, Poland

and more 32 locations